



1/5

SEQUENCE LISTING

<110> Abbott Laboratories  
Henkin, Jack  
Haviv, Fortuna  
Bradley, Michael F.  
Kalvin, Douglas M.  
Schneider, Andrew J.

<120> PEPTIDE ANTIANGIOGENIC DRUGS

<130> 6356.US.P3

<140> 09/447,226  
<141> 1999-11-22

<150> US 09/316,888  
<151> 1999-05-21

<150> US 60/126,546  
<151> 1999-03-26

<150> US 60/086,536  
<151> 1998-05-22

<160> 6

<170> FastSEQ for Windows Version 4.0

<210> 1  
<211> 10  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Antiangiogenetic Peptide

<221> VARIANT  
<222> (1)...(1)  
<223> Xaa = Ala, Asn, Cit, Gln, Glu, NEtGly, Met,  
N-methylalananyl, Pro, pyro-Glu, Sar, Ser, or Thr at  
position 1

<221> VARIANT  
<222> (2)...(2)  
<223> Xaa = Ala, Asn, Asp, Gln, Glu, Leu, Met, Phe, Pro,  
or Ser at position 2

<221> VARIANT  
<222> (3)...(3)  
<223> Xaa = Ala, Asn, Cit, Cha, Chg, Gln, Glu, Gly, Ile,  
Leu, Met, Nva, Phe, Ser, tButylgly, Thr, Val, Pen,  
or Cys at position 3

<221> VARIANT

<222> (4)...(4)  
 <223> Xaa = alloIle, Gly, Ile, Pro, or dehydroleu at position 4  
  
 <221> VARIANT  
 <222> (5)...(5)  
 <223> Xaa = Ala, 3-Pal, 1-Nal, 2-Nal, allo-threonyl, allylgly, Gln, Gly, His, Hser, Ile, Lys(Ac), Met, Nva, Octylgly, Orn, Phe(4-CH<sub>2</sub>OH), Pro, Ser, Thr, Trp, Tyr, Pen, or Cys at position 5  
  
 <221> VARIANT  
 <222> (6)...(6)  
 <223> Xaa = Ala, 1-Nal, 2-Nal, 3-Pal, Abu, allylgly, Arg, Asn, Asp, Cit, Cha, Gln, Glu, Gly, His, Homoala, Hle, Hser, Ile, Leu, Lys(Ac), Lys(Isp), at position 6  
  
 <221> VARIANT  
 <222> (6)...(6)  
 <223> 6 Cont'd:  
 Xaa = Met(O<sub>2</sub>), Met(O), Met, Nor, Nva, Octylgly, Phe, Phe(4-CONH<sub>2</sub>), Propargylgly, Ser, Thr, Trp, Tyr, Val, Pen, or Cys at position 6  
  
 <221> VARIANT  
 <222> (7)...(7)  
 <223> Xaa = Ala, Allylgly, Asn, Cit, Chg, Gln, Gly, Hser, Ile, alloIle, Leu, Lys(Ac), Met, 1-Nal, 2-Nal, Nva, Phe, Pro, Ser, tButylgly, Trp, Tyr, Val, Pen, or Cys at position 7  
  
 <221> VARIANT  
 <222> (8)...(8)  
 <223> Xaa = Aminopyrimidinobutanoyl, Ala(3-guanidino), Ala(3-pyrrolicinylamidino), Ala[4-Pip(N-amidino)], Arg, arginyl(WGNG'diethyl), Cit, Cha(4-NIsp), Gly[4-pip(N-amido)], at position 8  
  
 <221> VARIANT  
 <222> (8)...(8)  
 <223> 8 Cont'd:  
 Xaa = His, Harg, Lys, Lys(Ile), Lys(Nic), Norarg, Orn(Isp), Orn(Nic), Orn(2-imidazo), Phe(4-CH<sub>2</sub>NHIs), Phe(4-guanidino), or Phe(4-NIsp) at position 8  
  
 <221> VARIANT  
 <222> (9)...(9)  
 <223> Xaa = Abu, Aib, homoprolyl, hydroxyprolyl, Ile, Leu, Phe, Pro, Ser, tButylgly, Tic, Thr, or Val at position 9  
  
 <221> VARIANT  
 <222> (10)...(10)  
 <223> Xaa = azaglycylamide, glycylamide, glycylethylamide, sarcosylamide, serylamide at

3/5

position 10

<400> 1  
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa  
1 5 10

<210> 2  
<211> 9  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Antiangiogenetic peptide

<221> VARIANT  
<222> (1)...(1)  
<223> Xaa = sarcosyl at position 1

<221> VARIANT  
<222> (6)...(6)  
<223> Xaa = norvaline at position 6

<400> 2  
Xaa Gly Val Ile Thr Xaa Ile Arg Pro  
1 5

<210> 3  
<211> 9  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Antiangiogenetic peptide

<221> VARIANT  
<222> (1)...(1)  
<223> Xaa = sarcosyl at position 1

<221> VARIANT  
<222> (6)...(6)  
<223> Xaa = norvaline at position 6

<400> 3  
Xaa Gly Val Gly Thr Xaa Ile Arg Pro  
1 5

<210> 4  
<211> 9  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Antiangiogenetic peptide

<221> VARIANT  
 <222> (1)...(1)  
 <223> Xaa = sarcosyl at position 1

<221> VARIANT  
 <222> (4)...(4)  
 <223> Xaa = allo-isoleucyl at position 4

<221> VARIANT  
 <222> (6)...(6)  
 <223> Xaa = norvaline at position 6

<400> 4  
 Xaa Gly Val Xaa Thr Xaa Ile Arg Pro  
 1 5

<210> 5  
 <211> 9  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Antiangiogenic peptide

<221> VARIANT  
 <222> (1)...(1)  
 <223> Xaa = sarcosyl at position 1

<221> VARIANT  
 <222> (4)...(4)  
 <223> Xaa = dehydroleucyl at position 4

<221> VARIANT  
 <222> (6)...(6)  
 <223> Xaa = norvaline at position 6

<400> 5  
 Xaa Gly Val Xaa Thr Xaa Ile Arg Pro  
 1 5

<210> 6  
 <211> 11  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Antiangiogenic Peptide

<221> VARIANT  
 <222> (1)...(1)  
 <223> Xaa = R-(CH<sub>2</sub>)<sub>n</sub>-C(O)- where R is N-acetylamino at position 1

<221> VARIANT  
 <222> (2)...(2)

<223> Xaa = Sar at position 2

<221> VARIANT

<222> (5)...(5)

<223> Xaa = AlloIle, dehydroleu, Gly, Ile or Pro at position 5

<221> VARIANT

<222> (6)...(6)

<223> Xaa = Ala, 3-Pal, 1-Nal, 2-Nal, allo-threonyl, allylgly, Gln, Gly, His, Hser, Ile, Lys(Ac), Met, Nva, Octylgly, Orn, Phe(3-CH<sub>2</sub>OH), Pro, Ser, Thr, Trp, Tyr, Pen or Cys at position 6

<221> VARIANT

<222> (7)...(7)

<223> Xaa = Ala, 1-Nal, 2-Nal, 3-Pal, Abu, allylgly, Arg, Asn, Asp, Cit, Cha, Gln, Glu, Gly, His, Homoala, Hle, Hser, Ile, Leu, Lys(Ac), Lys(Isp), at position 7

<221> VARIANT

<222> (7)...(7)

<223> 7 Con'td:

Xaa = Met(O<sub>2</sub>), Met(O), Met, Nor, Nva, Octylgly, Phe, Phe(4-CONH<sub>2</sub>), Propargylgly, Ser, Thr, Trp, Tyr, Val, Pen, or Cys at position 7

<221> VARIANT

<222> (11)...(11)

<223> Xaa = Azaglycylamide, glycylamide, glycylethylamide, sarcosylamide, serylamine at position 11

<400> 6

Xaa Xaa Gly Val Xaa Xaa Xaa Ile Arg Pro Xaa  
1 5 10

A3  
Conclude